Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
1.23
Industry P/E
--
Debt to Equity
0
ROE
-0.83 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.3
CFO
$-22.81 Mln
EBITDA
$-18.60 Mln
Net Profit
$-17.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
XORTX Therapeutics (XRTX)
| -6.16 | 10.42 | 13.95 | -63.82 | -90.13 | 3.53 | -- |
|
BSE Sensex*
| 2.75 | 3.85 | 5.92 | 9.04 | 11.81 | 20.15 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
|
|---|---|---|---|---|
|
XORTX Therapeutics (XRTX)
| -50.81 | -99.61 | 1,667.24 | -11.25 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.67 | 200.22 | -- | 299.46 | |
| 7.12 | 191.83 | -- | -40.76 | |
| 1.66 | 229.53 | -- | -136.88 | |
| 0.60 | 19.23 | 5.35 | 33.7 |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third... phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada. Address: 3710 ? 33rd Street NW, Calgary, AB, Canada, T2L 2M1 Read more
Founder, CEO, President & Director
Dr. Allen Warren Davidoff Ph.D.
Founder, CEO, President & Director
Dr. Allen Warren Davidoff Ph.D.
Headquarters
Calgary, AB
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of XORTX Therapeutics Inc (XRTX) stood at $ 6 Mln as on 30-Sep-24
The share price of XORTX Therapeutics Inc (XRTX) is $1.06 (NASDAQ) as of 28-Apr-2025 16:18 EDT. XORTX Therapeutics Inc (XRTX) has given a return of -90.13% in the last 3 years.
XORTX Therapeutics Inc (XRTX) has a market capitalisation of $ 4 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of XORTX Therapeutics Inc (XRTX) is 1.23 times as on 28-Apr-2025, a 53% discount to its peers’ median range of 2.63 times.
Since, TTM earnings of XORTX Therapeutics Inc (XRTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the XORTX Therapeutics Inc (XRTX) and enter the required number of quantities and click on buy to purchase the shares of XORTX Therapeutics Inc (XRTX).
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada. Address: 3710 ? 33rd Street NW, Calgary, AB, Canada, T2L 2M1
The CEO & director of Dr. Allen Warren Davidoff Ph.D.. is XORTX Therapeutics Inc (XRTX), and CFO & Sr. VP is Dr. Allen Warren Davidoff Ph.D..
There is no promoter pledging in XORTX Therapeutics Inc (XRTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
23
|
|
|
20
|
|
|
18
|
|
|
2
|
| XORTX Therapeutics Inc. (XRTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-31.86
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of XORTX Therapeutics Inc (XRTX) was $0 Mln.
$-0.02
(
